HUP0102142A3 - Use of cyclosporins in the treatment of inflammatory autoimmune diseases - Google Patents

Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Info

Publication number
HUP0102142A3
HUP0102142A3 HU0102142A HUP0102142A HUP0102142A3 HU P0102142 A3 HUP0102142 A3 HU P0102142A3 HU 0102142 A HU0102142 A HU 0102142A HU P0102142 A HUP0102142 A HU P0102142A HU P0102142 A3 HUP0102142 A3 HU P0102142A3
Authority
HU
Hungary
Prior art keywords
cyclosporins
treatment
autoimmune diseases
inflammatory autoimmune
inflammatory
Prior art date
Application number
HU0102142A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0102142A2 publication Critical patent/HUP0102142A2/hu
Publication of HUP0102142A3 publication Critical patent/HUP0102142A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HU0102142A 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases HUP0102142A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811854.0A GB9811854D0 (en) 1998-06-02 1998-06-02 Organic compounds
PCT/EP1999/003770 WO1999062540A1 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Publications (2)

Publication Number Publication Date
HUP0102142A2 HUP0102142A2 (hu) 2001-11-28
HUP0102142A3 true HUP0102142A3 (en) 2001-12-28

Family

ID=10833083

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102142A HUP0102142A3 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Country Status (17)

Country Link
EP (1) EP1082130A1 (hu)
JP (2) JP4523154B2 (hu)
KR (1) KR20010043969A (hu)
CN (1) CN1304315A (hu)
AU (1) AU750422B2 (hu)
BR (1) BR9910860A (hu)
CA (1) CA2333315A1 (hu)
GB (1) GB9811854D0 (hu)
HU (1) HUP0102142A3 (hu)
ID (1) ID27576A (hu)
IL (1) IL139589A0 (hu)
NO (1) NO20006113L (hu)
PL (1) PL344451A1 (hu)
SK (1) SK18142000A3 (hu)
TW (2) TWI250021B (hu)
WO (1) WO1999062540A1 (hu)
ZA (1) ZA200006464B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1123001A (en) 1999-10-27 2001-05-08 Alexandra Lucas Compositions and methods for preventing and treating transplant rejection
CA2423313A1 (en) * 2000-09-29 2002-04-04 Z. Robert Zhong Methods of treating inflammatory and immune reactions and compositions therefor
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US20080194470A1 (en) * 2004-04-08 2008-08-14 Novartis Ag Nim811 In Cerebral Ischemia and Brain and Spinal Cord Injury
MX2007000503A (es) 2004-07-14 2007-03-08 Novartis Ag Uso de una combinacion de ciclosporina e interferon pegilado para el tratamiento de hepatitis c(hcv).
AU2005290984B2 (en) * 2004-10-01 2010-09-09 Debiopharm Sa Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
EP1830871A1 (en) 2004-12-23 2007-09-12 Novartis AG Compositions for hcv treatment
MX2007007721A (es) * 2004-12-23 2007-08-14 Novartis Ag Compuestos para el tratamiento de flaviviridae.
WO2006138507A1 (en) * 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
AU2009334790B2 (en) 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
EP2509615A1 (en) * 2009-12-09 2012-10-17 Scynexis, Inc. Novel cyclic peptides
WO2014049540A2 (en) 2012-09-29 2014-04-03 Novartis Ag Cyclic peptides and use as medicines
US20140212381A1 (en) * 2012-10-19 2014-07-31 Scynexis, Inc. Macrocycles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281B2 (en) * 1990-11-02 2000-11-22 Novartis AG Cyclosporins
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (es) * 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky

Also Published As

Publication number Publication date
TWI250022B (en) 2006-03-01
WO1999062540A1 (en) 1999-12-09
HUP0102142A2 (hu) 2001-11-28
AU4372499A (en) 1999-12-20
NO20006113L (no) 2001-01-25
IL139589A0 (en) 2002-02-10
GB9811854D0 (en) 1998-07-29
JP2002516873A (ja) 2002-06-11
BR9910860A (pt) 2001-03-06
JP2010059177A (ja) 2010-03-18
TW200522975A (en) 2005-07-16
JP4523154B2 (ja) 2010-08-11
PL344451A1 (en) 2001-11-05
ZA200006464B (en) 2002-03-11
CA2333315A1 (en) 1999-12-09
NO20006113D0 (no) 2000-12-01
AU750422B2 (en) 2002-07-18
SK18142000A3 (sk) 2001-06-11
EP1082130A1 (en) 2001-03-14
KR20010043969A (ko) 2001-05-25
ID27576A (id) 2001-04-12
CN1304315A (zh) 2001-07-18
TWI250021B (en) 2006-03-01

Similar Documents

Publication Publication Date Title
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
IL132318A0 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
IL142908A0 (en) Compounds useful in the treatment of inflammatory diseases
IL133766A0 (en) 2-substituted imidazoles useful in the treatment of inflammatory diseases
PL344451A1 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
IL144981A0 (en) Treatment of autoimmune disease
IL131025A0 (en) Treatment of autoimmune disease using tolerization in combination with methotrexate
IL148401A0 (en) Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
HUP0302194A3 (en) Chemokine mutants in the treatment of multiple sclerosis
HK1025954A1 (en) Triptolide derivatives useful in the treatment of autoimmune diseases
EP1079764A4 (en) TREATMENT OF SEXUALITY DISORDERS IN CERTAIN GROUPS OF PATIENTS
IL129024A0 (en) Use of proteins as agent against autoimmune diseases
GB9927757D0 (en) Treatment of autoimmune diseases
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
HUP0200354A3 (en) Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
HUP0200552A2 (en) Use of apoptosis inducing agents in the treatment of (auto)immune diseases
GB9603657D0 (en) Improvements in the treatment of vaginal infections
SI0983275T1 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
SI0966447T1 (en) Small molecules useful in the treatment of inflammatory disease
SI1011649T1 (en) Use of endipalene in the treatment of psoriasis
ZA978363B (en) Use of proteins as agents against autoimmune diseases.
GB9816352D0 (en) The treatment of inflammatory disorders
GB9816349D0 (en) The treatment of inflammatory disorders